Morgan Stanley notes that a court issued a permanent injunction on June 11 against Mylan, though the body of the order is currently sealed, so the firm cannot ascertain the details. With this injunction, the firm believes Mylan is enjoined from launching its Eylea biosimilar until the formulation patent expires in 2027, calling the news an “incremental positive” that should allow Regeneron more time to convert the market to Eylea high dose, or HD. The firm has an Overweight rating and $1,183 price target on Regeneron shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- Biotech Alert: Searches spiking for these stocks today
- Regeneron price target raised to $1,200 from $1,185 at RBC Capital
- FibroGen, Regeneron in deal for oncology assets in evaluation combo study
- Regeneron, Sanofi report FDA extension of target action date for Dupixent review